AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2003 SEP 4 - (NewsRx.com & NewsRx.net) -- Therapy that prevents bone loss also reverses cholesterol transport.
According to recent research from Germany, "nitrogen-containing bisphosphonates used in osteoporosis act by interference with pyrophosphorylated intermediates of the sterol pathway and are internalized by monocytes/macrophages, key players in atherogenesis. We therefore studied the effects of ibandronate on monocytic cholesterol homeostasis."
"In differentiated human MM6 cells and freshly prepared human peripheral blood monocyte cells (PBMCs) lipoprotein receptor transcription was quantified by real-time RT-PCR and receptor-mediated cellular cholesterol handling by lipoprotein-driven uptake and efflux assays," wrote D. Strobach and colleagues, University of Munchen Clinic.
"Low nanomolar concentrations of ibandronate reduced cellular cholesterol content despite reactive up-regulation of the LDL receptor. Simultaneously, the transcription of the cellular cholesterol exporter ABCA1 was several-fold stimulated, whereas the scavenger receptor CD36 was down-regulated. Thereby, ibandronate decreased the cellular uptake of modified LDL and enhanced the ...
Source: HighBeam Research, Therapy that prevents bone loss also reverses cholesterol transport.